P719: Vitamin and micronutrient excess in patients with Crohn’s disease under oral ambulatory exclusive enteral nutritionECCO'24Year: 2024
Authors: Oliveira, R.(1)*;Mendes, B.(2);Cunha Neves, J.(1);Amorim, E.(2);Roseira, J.(1);Tavares de Sousa, H.(1);
(1)Algarve University Hospital Centre, Gastroenterology Department, Portimão, Portugal;(2)Algarve University Hospital Centre, Colorectal Unit - General Surgery Department, Portimão, Portugal;
P720: Exit interviews exploring Crohn’s disease patients’ experience of changes in their bowel urgency during the mirikizumab Phase 3 clinical trial in adult patients with moderate to severe Crohn diseaseECCO'24Year: 2024
Authors: H. Gibble, T.(1);Macey, J.(2);Makin, H.(2);Rosu, R.(3);Mellor, K.(2);Kitchen, H.(2);Carlier, H.(4);Dubinsky, M.C.(5)*;
(1)Eli Lilly and Company, Value- Evidence- and Outcomes, Indianapolis, United States;(2)Clarivate, Clinical Outcomes Assessment, London, United Kingdom;(3)Eli Lilly and Company, Clinical Development, Indianapolis, United States;(4)Eli L, Medical, Indianapolis, United States;(5)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York City, United States;
P721: Dutch Crohn’s disease patients’ (pediatric and adult) perspectives of CDED diet and Modulife programECCO'24Year: 2024
Authors: Wijers, F.(1)*;van Zundert, S.(1);Verburgt, C.(2);van der Kruk, N.(2);van Limbergen, J.(2);Wierdsma, N.(1);
(1)Amsterdam University Medical Centers, Department of Nutrition and Dietetics, Amsterdam, The Netherlands;(2)Amsterdam University Medical Centers- Emma Children’s Hospital, Department of Pediatric Gastroenterology, Amsterdam, The Netherlands;
P722: The steep ramp test is a valid practical test to assess cardiorespiratory fitness in patients with inflammatory bowel diseaseECCO'24Year: 2024
Authors: Demers, K.(1,2,3,4)*;Bongers, B.C.(3,5);Jonkers, D.M.A.E.(2);Pierik, M.J.(2,4);Stassen, L.P.S.(1,3);
(1)Maastricht University Medical Center+, Department of Surgery, Maastricht, The Netherlands;(2)Maastricht University, Department of Gastroenterology-Hepatology- Research Institute for Nutrition and Translational Research in Metabolism NUTRIM, Maastricht, The Netherlands;(3)Maastricht University, Department of Surgery- Research Institute for Nutrition and Translational Research in Metabolism NUTRIM, Maastricht, The Netherlands;(4)Maastricht University Medical Center+, Department of Gastroenterology and Hepatology, Maastricht, The Netherlands;(5)Maastricht University, Department of Nutrition and Movement Sciences- Research Institute for Nutrition and Translational Research in Metabolism NUTRIM, Maastricht, The Netherlands;
P723: Upadacitinib in Crohn’s disease: Real world experience from an early access program in GreeceECCO'24Year: 2024
Authors: Papathanasiou, E.(1)*;Leonidakis, G.(1);Michalopoulos, G.(2);Manolakopoulos, S.(3);Siakavellas, S.(3);Theodoropoulou, A.(4);Tasovasili, A.(5);Giouleme, O.(6);Tzouvala, M.(7);Tsironi, E.(8);Viazis, N.(9);Michopoulos, S.(1);Zampeli, E.(1);
(1)General Hospital of Athens @D@Alexandra@D@, Department of Gastroenterology, Athens, Greece;(2)General Hospital of Athens @D@G. Gennimatas@D@, Department of Gastroenterology, Athens, Greece;(3)Hippocration General Hospital of Athens- University of Athens Medical School, Hepatogastroenterology Unit- 2nd Academic Department of Internal Medicine, Athens, Greece;(4)Venizeleio General Hospital, Department of Gastroenterology, Heraklion, Greece;(5)Academic Department of Internal Medicine- Hepatogastroenterology Unit- @D@Agioi Anargyroi@D@ General and Oncology Hospital of Kifisia- National and Kapodistrian University of Athens, Department of Gastroenterology, Athens, Greece;(6)Medical School- Aristotle University of Thessaloniki- Hippokration Hospital, Second Propedeutic Department of Internal Medicine, Thessaloniki, Greece;(7)General Hospital Nikaias-Piraeus @E@Agios Panteleimon@E@-General Hospital Dytikis Attikis @D@Agia Varvara@D@, Department of Gastroenterology, Athens, Greece;(8)Metaxa Memorial General Hospital, Department of Gastroenterology, Athens, Greece;(9)Evangelismos Hospital, Department of Gastroenterology, Athens, Greece;
P725: Predictive factors for biologic therapy initiation after ileal pouch-anal anastomosisECCO'24Year: 2024
Authors: Fischman, M.(1)*;Godny, L.(2,3);Friedeberg, A.(2,3);Barkan, R.(2,3);White, I.(3,4);Wasserberg, N.(3,4);Dotan, I.(2,3);Ollech, J.E.(2,3);
(1)Hebrew University of Jerusalem, Department of Military Medicine, Jerusalem, Israel;(2)Rabin Medical Center, Division of Gastroenterology, Petah Tikva, Israel;(3)Tel Aviv University, Faculty of Medicine, Tel Aviv, Israel;(4)Rabin Medical Center, Division of Surgery, Petah Tikva, Israel;
P726: A phase 2 study investigating the efficacy and safety of dupilumab versus placebo in adults with moderately to severely active ulcerative colitis with an eosinophilic phenotypeECCO'24Year: 2024
Authors: Gottlieb, E.(1)*;Binion, D.(2);Feagan, B.(3);Laws, E.(4);Nivens, C.(5);Maloney, J.(5);Abdulai, R.(4);Radin, A.(5);Glotfelty, L.(4);
(1)Sanofi, Sanofi, Stockholm, Sweden;(2)University of Pittsburgh Medical Center, Division of Gastroenterology- Hepatology and Nutrition, Pittsburgh- PA, United States;(3)Alimentiv Inc., Alimentiv Inc., London- ON, Canada;(4)Sanofi, Sanofi, Bridgewater- NJ, United States;(5)Regeneron Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Tarrytown- NY, United States;
P727: Clinical efficacy of apheresis in Ulcerative Colitis. The experience of four tertiary centers.ECCO'24Year: 2024
Authors: Papathanasiou, E.(1)*;Markopoulos, P.(2);Tzouvala, M.(3);Ioannou, A.(1);Tsironi, E.(2);Zacharopoulou, E.(3);Tzakri, M.(1);Pantelakis, E.(1);Leonidakis, G.(1);Bamias, G.(4);Michopoulos, S.(1);Zampeli, E.(1);
(1)@D@Alexandra@D@ General Hospital, Department of Gastroenterology, Athens, Greece;(2)Metaxa Memorial General Hospital, Department of Gastroenterology, Athens, Greece;(3)General Hospital Nikaias-Piraeus @E@Agios Panteleimon@E@-General Hospital Dytikis Attikis @D@Agia Varvara@D@, Department of Gastroenterology, Athens, Greece;(4)Sotiria Hospital- Medical School- National and Kapodistrian University of Athens, GI-Unit- 3rd Academic Department of Internal Medicine, Athens, Greece;
P731: Relapse rate following withdrawal of anti-TNF therapy in patients with inflammatory bowel disease: A single-center experienceECCO'24Year: 2024
Authors: SinaDr., M.(1)*;Pemaj, X.(1);Djegsi, A.(1);Telaku, S.(2);Prifti, S.(1);
(1)University Hospital Center Mother Theresa, Internal Medicine/ Gastroenterology, Tirana, Albania;(2)UBT, Internal Medicine/ Gastroenterology, Pristina, Kosovo;
P732: Lack of concordance between patient-reported, physician-reported and objective criteria-based identification of suboptimal control in IBD patients: IBD PODCAST study resultsECCO'24Year: 2024
Authors: D@E@Amico, F.(1)*;Gomollón, F.(2);Bamias, G.(3);Magro, F.(4);Heatta-Speicher, T.(5);Michelena, N.(6);Leitner, C.(7);Dignass, A.(8);
(1)IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Gastroenterology and Endoscopy, Milan, Italy;(2)Hospital Clínico Universitario “Lozano Blesa”, Facultad de Medicina, Zaragoza, Spain;(3)Sotiria Hospital- National & Kapodistrian University of Athens, GI-Unit- 3rd Academic Dpt. Of Internal Medicine, Athens, Greece;(4)Faculdade de Medicina da Universidade do Porto, CINTESIS@RISE Departament, Porto, Portugal;(5)AbbVie AS, Immunology, Oslo, Norway;(6)AbbVie Spain- SLU, Immunology, Madrid, Spain;(7)AbbVie Switzerland, Immunology, Cham, Switzerland;(8)Agaplesion Markus Hospital- Goethe University, Department of Medicine I, Frankfurt am Main, Germany;on behalf of the IBD-Podcast study group
P733: Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases treated with intensified doses: the REMSWITCH-LT studyECCO'24Year: 2024
Authors: Buisson, A.(1)*;Nachury, M.(2);Bazoge, M.(3);Yzet, C.(4);Wils, P.(2);Dodel, M.(1);Coban, D.(1);Pereira, B.(1);Fumery, M.(4);
(1)CHU Clermont-Ferrand, IBD Unit, Clermont-Ferrand, France;(2)CHRU Lille, IBD Unit, Lille, France;(3)CHU Clermont-Ferrand, IBD Unit, Clermont-Ferrabd, France;(4)CHU Amiens, IBD Unit, Amiens, France;
P734: Super-responders in patients with moderate-to-severe Crohn’s disease treated with subcutaneous infliximab maintenance therapy: A post hoc analysis of the LIBERTY-CD studyECCO'24Year: 2024
Authors: Schreiber, S.W.(1)*;Sands, B.E.(2);Hanauer, S.B.(3);Danese, S.(4);Loftus Jr, E.V.(5);Jeong, A.L.(6);Kim, D.H.(6);Lee, Y.N.(6);Colombel, J.F.(2);
(1)University Hospital Schleswig-Holstein, Department of Medicine I, Kiel, Germany;(2)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(3)Northwestern University- Feinberg School of Medicine, Division of Gastroenterology and Hepatology- Department of Medicine, Chicago, United States;(4)IRCCS San Raffaele Hospital and Vita-Salute University, Department of Gastroenterology, Milan, Italy;(5)Mayo Clinic College of Medicine and Science, Division of Gastroenterology and Hepatology, Rochester, United States;(6)Celltrion Healthcare Co.- Ltd, Not applicable, Incheon, Korea- Republic Of;
P735: JAK inhibitors and S1P receptor modulators for the treatment of antibiotic refractory chronic pouchitis: an ECCO CONFER Multicentre Case SeriesECCO'24Year: 2024
Authors: Testa, G.(1)*;Ribaldone, D.G.(1);Verstockt, B.(2,3);Molnar, T.(4);Savarino, E.(5);Schmidt, C.(6,7);Vieujean, S.(8);Teich, N.(9);Meianu, C.(10,11);Juillerat, P.(12,13);Grellier, N.(14);Lobaton, T.(15,16);
(1)University of Turin, Department of Medical Sciences- Division of Gastroenterology, Turin, Italy;(2)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(3)KU Leuven, Department of Chronic Diseases and Metabolism, Leuven, Belgium;(4)University of Szeged, University of Szeged, Szeged, Hungary;(5)University of Padua, Department of Surgery Oncology and Gastroenterology DiSCOG - Division of Gastroenterology, Padua, Italy;(6)Hospital Fulda, Medical Clinic II, Fulda, Germany;(7)Friedrich Schiller University, Medical Faculty, Jena, Germany;(8)University Hospital CHU of Liège, Hepato-Gastroenterology and Digestive Oncology, Liège, Belgium;(9)Gastroenterology Practice, Gastroenterology Practice, Leipzig, Germany;(10)Carol Davila University of Medicine and Pharmacy, Faculty of Medicine, Bucharest, Romania;(11)Fundeni Clinical Institute, Gastroenterology Department, Bucharest, Romania;(12)Bern University Hospital - Clinic for Visceral Surgery and Medicine, Department of Gastroenterology, Bern, Switzerland;(13)Gastro-enterologie Beaulieu SA, Crohn and Colitis Center, Lausanne, Switzerland;(14)University Hospital of Poitiers, Hepato-Gastroenterology Department, Poitiers, France;(15)Ghent University, Department of Internal Medicine and Pediatrics-, Ghent, Belgium;(16)University Hospital Ghent, Department of Gastroenterology, Ghent, Belgium;
P738: Response to etrasimod treatment in ulcerative colitis is associated with a reduction of circulating B and pro-inflammatory T cells: a single-cell-based post-hoc sub-analysis of the ELEVATE UC 52 trialECCO'24Year: 2024
Authors: Weidinger, C.(1)*;Milek, M.(2);Hecker, J.(1);Haag, L.M.(1);Freise, I.(1);Obermayer, B.(2);Beule, D.(2);Ryan, R.D.(3);Crosby, C.(3);Siegmund, B.(1);
(1)Charité – Universitätsmedizin Berlin- corporate member of Freie Universität Berlin and Humboldt -Universität zu Berlin, Department of Gastroenterology- Infectious Diseases and Rheumatology, Berlin, Germany;(2)Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Core Unit Bioinformatics, Berlin, Germany;(3)Pfizer Inc., Pfizer Inc., La Jolla- CA, United States;
